Millions of people worldwide take GLP-1 medications.

GLP-1 drugs must now carry a warning label about a potential link to a rare eye condition that can result in vision loss, the U.S. Food and Drug Administration announced on Nov. 9. 2026. The eye condition is called non-arteritic anterior ischemic optic neuropathy, or NAION, and doctors often refer to it as a stroke of the eye.

I am a clinician and epidemiologist who has studied GLP-1 drugs, and my colleagues and I published one of the studies that identified a link between GLP-1 drugs and NAION.

Originally published on theconversation.com, part of the BLOX Digital Content Exchange.